US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
FDA approval can significantly boost sales and market position, as seen with other antibiotics previously receiving similar approvals.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
FDA approval can significantly boost sales and market position, as seen with other antibiotics previously receiving similar approvals.
What happened, with direct paths to the underlying reporting
Innoviva's antibiotic received FDA approval for treating a common STI. This offers a convenient oral treatment alternative to current injection methods.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.